(Q44658636)

5 December 2017

title

KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy (English)

1 reference

5 December 2017

1 reference

12

1 reference

5 December 2017

Ji-lin Guan

1

1 reference

5 December 2017

Wen-zhao Zhong

2

1 reference

5 December 2017

She-juan An

3

1 reference

5 December 2017

Jin-ji Yang

4

1 reference

5 December 2017

Jian Su

5

1 reference

5 December 2017

Zhi-hong Chen

6

1 reference

5 December 2017

Hong-hong Yan

7

1 reference

5 December 2017

Zhi-yong Chen

8

1 reference

5 December 2017

Zhi-min Huang

9

1 reference

5 December 2017

Xu-chao Zhang

10

1 reference

5 December 2017

Qiang Nie

11

1 reference

5 December 2017

publication date

4 December 2012

1 reference

Annals of Surgical Oncology

5 December 2017

published in

1 reference

5 December 2017

volume

20

1 reference

5 December 2017

issue

4

1 reference

5 December 2017

page(s)

1381-1388

1 reference

New driver mutations in non-small-cell lung cancer

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

KRAS mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

K-ras mutations in non-small-cell lung carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Are RAS mutations predictive markers of resistance to standard chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2754-Z

10.1245/S10434-012-2754-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

5 December 2017

1005321664

0 references

1 reference